Ubs Group Ag Halozyme Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 331,330 shares of HALO stock, worth $17.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

331,330

Previous 415,406 20.24%

Holding current value

$17.2 Million

Previous $15.4 Million 12.21%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$33.68 - $41.95 $2.83 Million - $3.53 Million	-84,076 Reduced 20.24%	331,330 $13.5 Million
Q4 2023 Feb 09, 2024	BUY	$33.32 - $42.1 $7.58 Million - $9.58 Million	227,518 Added 121.09%	415,406 $15.4 Million
Q3 2023 Nov 09, 2023	SELL	$36.46 - $44.03 $635,825 - $767,839	-17,439 Reduced 8.49%	187,888 $7.18 Million
Q2 2023 Aug 11, 2023	BUY	$30.28 - $38.74 $793,578 - $1.02 Million	26,208 Added 14.63%	205,327 $7.41 Million
Q1 2023 May 12, 2023	BUY	$32.86 - $55.7 $1.04 Million - $1.77 Million	31,735 Added 21.53%	179,119 $6.84 Million

Q4 2022 Feb 08, 2023	BUY	$40.06 - $59.44 $3.93 Million - $5.84 Million	98,207 Added 199.7%	147,384 $8.39 Million
Q3 2022 Nov 10, 2022	SELL	$38.53 - $51.78 $1.14 Million - $1.54 Million	-29,695 Reduced 37.65%	49,177 $1.94 Million
Q2 2022 Aug 10, 2022	SELL	$37.35 - $48.3 $449,021 - $580,662	-12,022 Reduced 13.23%	78,872 $3.47 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $2.73 Million - $3.51 Million	-85,419 Reduced 48.45%	90,894 $3.63 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $429,983 - $550,654	13,513 Added 8.3%	176,313 $7.09 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $3.07 Million - $3.7 Million	79,807 Added 96.16%	162,800 $6.62 Million
Q2 2021 Aug 13, 2021	SELL	$38.84 - $51.31 $3.06 Million - $4.05 Million	-78,857 Reduced 48.72%	82,993 $3.77 Million
Q1 2021 May 12, 2021	BUY	$39.51 - $51.45 $2.15 Million - $2.79 Million	54,315 Added 50.51%	161,850 $6.75 Million
Q4 2020 Feb 11, 2021	BUY	$25.81 - $43.62 $960,261 - $1.62 Million	37,205 Added 52.9%	107,535 $4.59 Million
Q3 2020 Nov 12, 2020	SELL	$25.74 - $29.63 $55,855 - $64,297	-2,170 Reduced 2.99%	70,330 $1.85 Million
Q2 2020 Jul 31, 2020	SELL	$16.25 - $26.81 $732,062 - $1.21 Million	-45,050 Reduced 38.32%	72,500 $1.94 Million
Q1 2020 May 01, 2020	SELL	$13.9 - $21.83 $874,754 - $1.37 Million	-62,932 Reduced 34.87%	117,550 $2.11 Million
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $532,060 - $695,990	-35,637 Reduced 16.49%	180,482 $3.2 Million
Q3 2019 Nov 14, 2019	BUY	$15.2 - $17.69 $1.23 Million - $1.43 Million	80,977 Added 59.92%	216,119 $3.35 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $785,570 - $919,250	53,259 Added 65.04%	135,142 $2.32 Million
Q1 2019 May 14, 2019	SELL	$13.94 - $17.58 $1.68 Million - $2.12 Million	-120,852 Reduced 59.61%	81,883 $1.32 Million
Q4 2018 Feb 14, 2019	BUY	$13.33 - $18.66 $1.4 Million - $1.96 Million	105,200 Added 107.86%	202,735 $2.97 Million
Q3 2018 Nov 14, 2018	BUY	$16.68 - $18.41 $503,635 - $555,871	30,194 Added 44.84%	97,535 $1.77 Million
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $1.96 Million - $2.36 Million	-116,215 Reduced 63.31%	67,341 $1.14 Million
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $1.72 Million - $2.14 Million	100,813 Added 121.84%	183,556 $3.6 Million
Q4 2017 Feb 14, 2018	SELL	$16.75 - $20.8 $505,247 - $627,411	-30,164 Reduced 26.72%	82,743 $1.68 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $245,501 - $363,242	20,876 Added 22.68%	112,907 $1.96 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-12,130 Reduced 11.65%	92,031 $1.18 Million
Q1 2017 Nov 14, 2017	BUY	N/A	104,161	104,161 $1.35 Million

Others Institutions Holding HALO

# of Institutions

442

Shares Held

122M

Call Options Held

216K

Put Options Held

140K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.24B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account